137 related articles for article (PubMed ID: 14665350)
21. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
22. Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer.
Gore JL; Penson DF; Litwin MS
Nat Clin Pract Urol; 2006 Aug; 3(8):449-52. PubMed ID: 16902521
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer diagnosed in spinal cord-injured patients is more commonly advanced stage than in able-bodied patients.
Scott PA; Perkash I; Mode D; Wolfe VA; Terris MK
Urology; 2004 Mar; 63(3):509-12. PubMed ID: 15028447
[TBL] [Abstract][Full Text] [Related]
24. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
[TBL] [Abstract][Full Text] [Related]
25. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.
Konety BR; Cowan JE; Carroll PR;
J Urol; 2008 May; 179(5):1797-803; discussion 1803. PubMed ID: 18343440
[TBL] [Abstract][Full Text] [Related]
26. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
27. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
28. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
[TBL] [Abstract][Full Text] [Related]
29. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
30. [Prostate cancer in the Community of Madrid in the year 2000. IV. Treatment].
Herranz Amo F; Arias Funez F; Arrizabalaga Moreno M; Calahorra Fernández FJ; Carballido Rodríguez J; Diz Rodríguez R; Herrero Payo JA; Llorente Abarca C; Martín Martínez JC; Martínez-Piñeiro Lorenzo L; Mínguez Martínez R; Moreno Sierra J; Rodríguez Antolín A; Tamayo Ruíz JC; Turo Antona J
Actas Urol Esp; 2003 Jun; 27(6):418-27. PubMed ID: 12918148
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.
Davison BJ; Oliffe JL; Pickles T; Mroz L
Oncol Nurs Forum; 2009 Jan; 36(1):89-96. PubMed ID: 19136342
[TBL] [Abstract][Full Text] [Related]
32. Present and future management of prostate cancer.
de Vere White R
Cancer Biother Radiopharm; 2000 Apr; 15(2):121-5. PubMed ID: 10803316
[No Abstract] [Full Text] [Related]
33. Prognostic significance of obstructive uropathy in advanced prostate cancer.
Oefelein MG
Urology; 2004 Jun; 63(6):1117-21. PubMed ID: 15183963
[TBL] [Abstract][Full Text] [Related]
34. Cross-sectional survey of long-term quality of life after radical perineal prostatectomy.
Yang BK; Crisci A; Young MD; Silverstein AD; Peterson BL; Dahm P
Urology; 2005 Jan; 65(1):120-5. PubMed ID: 15667876
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.
Harlan LC; Potosky A; Gilliland FD; Hoffman R; Albertsen PC; Hamilton AS; Eley JW; Stanford JL; Stephenson RA
J Natl Cancer Inst; 2001 Dec; 93(24):1864-71. PubMed ID: 11752011
[TBL] [Abstract][Full Text] [Related]
36. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
37. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
Yan Y; Carvalhal GF; Catalona WJ; Young JD
Cancer; 2000 Mar; 88(5):1122-30. PubMed ID: 10699903
[TBL] [Abstract][Full Text] [Related]
38. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
Lunardi P; Ploussard G; Grosclaude P; Roumiguié M; Soulié M; Beauval JB; Malavaud B
World J Urol; 2017 Apr; 35(4):587-593. PubMed ID: 27443847
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
40. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.
Meng MV; Elkin EP; Harlan SR; Mehta SS; Lubeck DP; Carroll PR
J Urol; 2003 Dec; 170(6 Pt 1):2279-83. PubMed ID: 14634396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
